Desmopressin in the treatment of women's bleeding disorders.
Bleeding disorders in women are an underestimated problem that deserves increased attention. About 9%-14% of females have menorrhagia and, amongst them, there is a significant over-representation of von Willebrand disease (VWD), with a prevalence of 13% in this group as compared with about 1% in the general population. The bleeding disorder has not been diagnosed in most of these women and they may therefore be withheld from treatment with desmopressin, which is effective in most cases of VWD and also in platelet dysfunctions and mild factor VIII deficiency. This paper is a review of the haemostatic use of desmopressin with special reference to women's bleeding disorders, the mechanisms of action, modes of administration, clinical indications, dosage recommendations, and hospital or home treatment. Desmopressin stimulates endogenous release of FVIII and von Willebrand factor (VWF), it increases platelet adhesiveness and shortens bleeding time. It can be given as intravenous or subcutaneous injection, but the intranasal spray is probably the most practical mode of administration for females with bleeding disorders as it is simple to administer and suitable for home treatment. The spray has been used successfully in connection with menorrhagia and other bleeding symptoms.
Lethagen
S
S
Department for Coagulation Disorders, Lund University, University Hospital, Malmö, Sweden.
D016063:Blood Loss, Surgical / Q000517:prevention & control; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006474:Hemorrhagic Disorders / Q000188:drug therapy*; D006490:Hemostatics / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D006473:Postpartum Hemorrhage / Q000188:drug therapy; D011247:Pregnancy; D012646:Self Administration
D006490:Hemostatics; D003894:Deamino Arginine Vasopressin